Skip to main content

GPC Biotech Forms Proteomics Alliance with Aventis Pharma

NEW YORK, Dec 15 - GPC Biotech of Munich and Aventis announced a proteomics
collaboration Friday, in which GPC will use its Pathcode protein interaction
mapping technology to find and validate compounds that interact with a drug
target Aventis has previously identified.

The parties did not disclose the financial terms of the agreement.

This collaboration follows two other joint projects between GPC and Aventis,
one in which GPC used Pathcode to discover new antifungal targets and
another three-year project in which the companies are using genomics and
proteomics technology to identify and validate osteoarthritis drug targets.

Pathcode detects protein-protein interactions using yeast hybrid cells and
is designed to run in a high-throughput manner. GPC Biotech also offers
other proteomic and genomic technologies, such as its Reverse Genomics
cell-based screens of drug targets, to pharma and biotech companies.

In addition to Aventis, GPC also has deals with Bayer, Dupont, Boehringer
Ingelheim, Altana, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems,
Morphosys and Karo Bio USA.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.